Skip to main content

Research Repository

Advanced Search

BreatheMOR: Morphine for the relief of breathlessness in stable chronic heart failure

People Involved

Professor Andrew Clark

Project Description

Opioids have been used for centuries to relieve pain and other symptoms. A meta-analysis in 2002 of eight randomised controlled trials (RCTs) showed that opioids had a clinically relevant beneficial effect on dyspnoea in people with mainly chronic obstructive pulmonary disease (COPD) or cancer, but few of these studies included people with chronic heart failure (CHF)(1). Chronic refractory dyspnoea despite optimal cardiac management remains a common and distressing problem for people with advanced CHF, and their carers. It leads to prolonged and heavy use of NHS resources, including unscheduled hospital admission. To our knowledge there are no other substantive pharmacological studies primarily directed at the relief of chronic refractory dyspnoea in people with CHF other than those below conducted by members of our research collaboration and it remains a seriously under-researched area.

Type of Project Project
Project Acronym BreatheMOR
Status Project Complete
Funder(s) British Heart Foundation
Value £299,581.00
Project Dates Oct 1, 2013 - Feb 28, 2019

You might also like

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Dec 31, 2019
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.Read More

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Apr 1, 2017 - Jul 31, 2021
Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study dru... Read More